**QUEEN'S
UNIVERSITY
BELFAST**

Development of Polycaprolactone-Based metronidazole matrices for intravaginal extended drug delivery using a mechanochemically prepared therapeutic deep eutectic system

Li, S., Culkin, A., Jones, D. S., & Andrews, G. P. (2021). Development of Polycaprolactone-Based metronidazole matrices for intravaginal extended drug delivery using a mechanochemically prepared therapeutic deep eutectic system. *International Journal of Pharmaceutics*, 593, [120071]. <https://doi.org/10.1016/j.ijpharm.2020.120071>

Published in:
International Journal of Pharmaceutics

Document Version:
Peer reviewed version

Queen's University Belfast - Research Portal:
[Link to publication record in Queen's University Belfast Research Portal](#)

Publisher rights

Copyright 2020 Elsevier.

This manuscript is distributed under a Creative Commons Attribution-NonCommercial-NoDerivs License

(<https://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.

General rights

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

1 Development of Polycaprolactone-Based Metronidazole Matrices for Intravaginal Extended
2 Drug Delivery Using a Mechanochemically Prepared Therapeutic Deep Eutectic System
3

4 Shu Li^{1,2*}, Alice Culkin¹, David S Jones¹, Gavin P Andrews^{1,2}
5

6 ¹ The Pharmaceutical Engineering Group, School of Pharmacy, Queen's University Belfast,
7 97 Lisburn Road, Belfast, Northern Ireland, UK, BT9 7BL.

8 ² China Medical University - Queen's University Belfast joint College (CQC), No.77 Puhe
9 Road, Shenyang North New Area, Shenyang, Liaoning Province, P.R. China.
10

11 *Correspondence to: Dr Shu Li (Tel: +44-28-9097-2367, E-mail: s.li@qub.ac.uk)

ABSTRACT

The engineering of crystalline multi-component drug systems, including cocrystals and salts, is now an established method of modifying the physicochemical properties and dissolution behaviour of an active ingredient. Remarkably, liquid drug systems, including therapeutic ionic liquids and therapeutic deep eutectic solvents (THEDES), remain largely unexplored as an untapped reservoir for drug modification. In this work, the formation of a THEDES containing metronidazole (MET), the preferred first-line treatment for bacterial vaginosis (BV), was explored. The formed THEDES was evaluated for its dissolution behaviour from a simple polycaprolactone (PCL) matrix, in order to achieve an extended release, balanced with an appropriate onset of action, hence offering improved MET intravaginal application. To minimise handling of the liquid THEDES, an end-to-end continuous process that enables feeding of the raw materials in their respective solid forms, and collection of a solidified final formulation is presented. The concurrent THEDES formation and formulation were carried out using a bench scale (approx. 10g) twin-screw hot melt extruder. The chosen parent reagents have shown sufficiently strong reactivity and resulted in successful and complete conversion to THEDES while in the presence of PCL, during the extrusion process. The formulated THEDES-PCL matrix exhibited significantly improved onset of drug release followed by a controlled delivery of MET over a total 7-day period in SVF, proving itself as a viable alternative to oral therapy.

KEYWORDS: Therapeutic deep eutectic, multi-component pharmaceutical materials, metronidazole, polycaprolactone, hot melt reactive extrusion, mechanochemical preparation, intravaginal delivery, antimicrobial, extended release.

1. INTRODUCTION

Bacterial vaginosis (BV), a common type of vaginitis, is a widespread disorder of the female population and one of the most widely studied gynaecological diseases. BV can be associated with diseases such as pelvic inflammatory disease, endometritis and vaginal cuff cellulitis after invasive procedures. Unfortunately, this can lead to serious complications including stomach pain, infertility and pre-term birth (Darwish et al., 2007). Treatment regimens for BV and other common forms of vaginitis (e.g., trichomoniasis and yeast infections) are recommended to not only resolve primary symptoms, but also to reduce the risk of developing secondary sexually transmitted infections including chlamydia, gonorrhoea, trichomonas vaginalis, herpes simplex virus type 2 infections and, human immunodeficiency virus (HIV) (Jones, 2019; Myer et al., 2005). Current NICE guidelines recommend metronidazole (MET) as a preferred first-line agent for BV treatment and management (Pal et al., 2011). The Centers for Disease Control and Prevention (CDC) also recommends within sexually transmitted diseases (STD) treatment guidelines, the use of MET for those at risk of STDs due to development of BV (Centers for Disease Control and Prevention, 2015). The common regimen for such applications is either twice daily oral administration of MET 500 mg tablets for a course of 7 days, or 0.75% MET gel used intravaginally at bedtime for 5 days. Both administration routes have been shown to offer similar therapeutic efficacies, with oral administration typically causing gastrointestinal irritation (Hanson et al., 2000). Oral MET tablets also suffer from poor patient compliance and sub-optimal performance due to additional significant adverse effects including greater prevalence of drug-drug interactions and poor patient tolerability. More recently, oral antibiotic treatments have also been reported to result in potentially unnecessary exposure to systemic antibiotics, and thus greater risks for developing antimicrobial resistance (AMR) (Smith, 2018; Turgut and Ozyazici, 2004; Zhang et al., 2013). Intravaginal delivery using gels, on the other hand offer localised targeting to the site of infection (Cunningham et al., 1994) whilst circumventing risks often associated with systemic exposure. These formulations, however, can be messy, uncomfortable, problematic in terms of drug content uniformity and suffer from formulation leakage. To address these issues and hence improve patient adherence, solid dosage forms such as vaginal tablets, suppositories and ring-shaped vaginal inserts are often used instead. However, these long-term implantable devices are typically made of either polymeric matrices that have significantly prolonged biodegradation profiles, or silicone based matrices that require removal after release of drug.

Amongst a number of biodegradable polymeric excipients, polycaprolactone (PCL) has been studied as a promising matrix carrier for extended release intravaginal dosage forms (Dang et al., 2013; Pathak et al., 2018, 2015, 2014), owing to its biocompatible nature, its established non-toxicity to the human body (Wan et al., 2009), as well as the fact that it can be completely excreted from the human body once bioabsorbed (Ramanujam et al., 2018). PCL has also been previously formulated with MET for dental applications (Lan et al., 2013), and has been used to prepare matrices for a controlled 7-day release of tinidazole for intravaginal administration (Fernando et al., 2019). These reported formulations, however, required either the formation of a blend between PCL and a hydrophilic polymer (such as alginate), or the generation of microporous structures within the PCL architecture, to achieve suitable drug release properties. In addition to the abovementioned modifications to PCL's biodegradation profile, we propose in this work, an alternative strategy to reduce the timeline required for complete drug release from PCL matrices via modification of the active ingredient and its dissolution behaviour.

Over the last decade, there has been significant interest in the use of multicomponent drug systems as a means of offering modified drug properties and drug dissolution behaviour. Examples include pharmaceutical co-crystals, small molecule co-amorphous systems and organic pharmaceutical salts. Using these complex guest molecule/counter-ion supramolecular structures, modification of physicochemical properties such as melting point, stability, aqueous solubility and the rate of dissolution may be achieved. Traditionally, solid forms (co-crystals, salts, polymorphs and/or hydrates) of these multi-component systems have been favoured due to ease of handling and general acceptance within the industry. Interestingly, liquid counterparts are often overlooked and represent an area that requires further investigation. In particular, the scientific literature is devoid of articles describing the fundamental characterisation and behaviour of multi-component liquid systems. This may be due to a general dislike of handling liquid substances and intermediates particularly during preparation of conventional dosage forms, the requirement for atypical characterisation tools to assure product quality, and very importantly, gaps in regulatory guidelines.

Despite having a more uncertain and complex development landscape, there is growing interest in these unexplored liquid drug systems (Aroso et al., 2016; Shamshina et al., 2013; Sheldon, 2017; Stoimenovski et al., 2010). Indeed, there is evidence within the literature to suggest that these complex liquid systems represent an untapped resource for drug enablement.

One major thrust of recent academic research has focused on liquid drug intermediates, namely pharmaceutically active ionic liquids (ILs). Generally regarded as third generation ILs, these complex liquid systems will involve an ionic API of interest and a second ionic component, that being, a second API or a biologically inactive component, that is present to enhance the physicochemical properties of the parent API. Moreover, therapeutic ILs offer zero waste and leave no waste product in their synthesis, are regarded as offering significantly ‘green’ processing, a factor that is increasingly important for an industry operating in a more socially responsible environment (Sheldon, 2017). Despite their significant advantages, according to the current FDA guidance, each new IL combination is considered a new chemical entity, and thus requires extensive toxicological testing before use in humans (Pedro et al., 2019). Therapeutic deep eutectic solvents (THEDES) (liquid equivalents to co-crystals) are a relatively new class of liquid molecular adduct that are liquids at room temperature. These innovative liquids consist of an intimate mixture of two components that interact through a variety of non-covalent interactions, including hydrogen bonding (H-bonding) and Van der Waals interactions (Abbott et al., 2017). Traditionally, a deep eutectic solvent (DES) consists of a Lewis or Brønsted acid and base, such as a carboxylic acid and choline bicarbonate, which strongly interact through H-bonding (Abbott et al., 2004). THEDES have been previously reported, and in these cases at least one of the components in the liquid molecular adduct is a pharmaceutically active ingredient (Aroso et al., 2015). Similar to solid co-crystals, which are bonded via non-ionic non-covalent forces, the regulatory review and testing of THEDESs is considerably more straightforward relative to therapeutic ILs. There are relatively limited examples of THEDESs on the market, however there are examples of marketed eutectic mixtures containing APIs. For example, EMLA® cream, which consists of an equimolar mixture of lidocaine and prilocaine and used for enhanced transdermal delivery and improved local absorption of both local anaesthetics (Wagner et al., 2006). Another THEDES product on the market is the S-Caine™ Peel, a topical anaesthetic which contains a eutectic mixture of lidocaine and tetracaine for effective pain relief for patients undergoing pulsed dye laser (PDL) treatment (Bryan et al., 2002). The same equimolar mixture of lidocaine and tetracaine is also marketed as Pliaglis®, which is used for dermatologic laser procedures, due to its fast-acting and efficacious performance (Alster, 2013).

When designing liquid molecular adducts such as ILs and THEDES, typical considerations include the nature of the components and the predicted interactions that can occur between them, through intentionally avoiding pairing components which would yield common

143 supramolecular synthons that may lead to crystallisation. This approach adopted in selecting
144 materials has been referred to as the ‘anti-crystal engineering’ approach (Dean et al., 2009),
145 which avoids pairing molecules based on a supramolecular synthon approach to avoid
146 crystallisation of a solid multi-component system. As a result, design of a neutral liquid
147 molecular adduct can prove challenging due to the many possible interactions that may occur,
148 and is often based on trial and error (Cherukuvada and Nangia, 2013). In this work, a number
149 of acidic compounds (respective structures shown in Table 1), which were selected based upon
150 a set of preliminary screening criteria, were investigated for feasibility to form a THEDES with
151 MET; the structure of these compounds are shown in Figure 1. The eutectic point of the most
152 promising system, MET-maleic acid (MA), was determined using a binary thermal phase
153 diagram (Yamashita et al., 2014).

154
155 This article extends recent work within the literature and provides a means by which a
156 THEDES system may be used to offer clinically optimal dosage forms. For the first time, we
157 report the use of THEDES technology to modify the drug release properties of MET from a
158 simple PCL matrix, to achieve a balance of rapid onset of action and an extended drug release
159 for improved MET intravaginal application. To minimise handling of the liquid THEDESs, an
160 end-to-end continuous process that enables feeding of the raw materials in their respective solid
161 forms, and collection of a solidified final formulation is described. In our previous work, we
162 have demonstrated the viability of hot-melt extrusion (HME) to offer a means by which co-
163 crystal synthesis may be achieved concurrently with drug product manufacture in a single-step
164 continuous process (Li et al., 2018, 2016). Here, we extend this work by adapting HME
165 technology for the production of vaginal implant that may offer enhanced clinical performance
166 and develop an enhanced THEDES-PCL system for intravaginal delivery of MET.

2. MATERIALS AND METHODS

2.1. Materials

Metronidazole was a kind gift from Farchemia Srl (Treviglio, Italy). Maleic acid and polycaprolactone were purchased from Sigma Aldrich (Dorset, UK). All other chemical reagents used were of analytical grade.

2.2. Liquid-Assisted Grinding (LAG)

LAG was used in this work to: (1) confirm the feasibility of forming a THEDES between the chosen reagents, and (2) prepare samples for subsequent thermal analysis and phase diagram construction. MET and MA were added to the ball milling chamber (MM200, Retsch, Germany) in differing molar ratios (MET:MA 9:1, 4:1, 7:3, 2:1, 1:1, 2:3, 1:2, 1:4 and 1:9) along with two drops of methanol and two 15 mm stainless steel milling balls. The mixtures were ground for 20 min consecutively at 22 Hz.

2.3. Thermogravimetric Analysis (TGA)

The thermal stability of each compound (5 – 10 mg) was investigated using a Thermal Advantage model TA Q100 (TA Instruments, UK). Ramp tests were carried out at a heating rate of 10 °C/min in the range of 25 – 300 °C. In order to maintain an inert environment, dry nitrogen was used as the purge gas at a flow rate of 60 mL/min for the sample chamber and 40 mL/min for the balance chamber.

2.4. Differential Scanning Calorimetry (DSC)

DSC (Thermal Advantage model Q20, TA Instruments, UK) was used to characterize the thermal behaviour of all raw ingredients, physical mixtures between MET and MA at various molar ratios, the liquid molecular adducts formed during LAG, physical mixtures of the extruded formulations and, the extrudates. The instrument was calibrated using indium and zinc prior to use. Samples (3 – 10 mg) were accurately weighed and transferred into aluminium pans which were subsequently crimped with aluminium lids. Samples were equilibrated at -65 °C, before being heated to 160 °C. A heating rate of 10 °C/min was employed, with nitrogen being used as the purge gas at 50 mL/min.

2.5. Attenuated total reflectance – Fourier Transform infrared spectroscopy (ATR FT-IR)

IR spectra were obtained on a Perkin-Elmer infrared spectrophotometer coupled with an Universal ATR sampling accessory (Spectrum Two FT-IR Spectrometer, Perkin-Elmer Instruments, USA). Data was collected across a range from 4000 to 650 cm^{-1} at a resolution of 4 cm^{-1} (16 scans). Data was plotted as transmittance (%) over wavenumber (cm^{-1}) and processed using Spectrum IR (Perkin-Elmer, USA).

2.6.Hot-Melt Extrusion (HME)

Physically blended mixtures of MET and MA, with and without PCL (10 and 20 % w/w MET), were manually fed into a corotating twin-screw bench-top extruder (HAAKE Minilab, Staffordshire, U.K.) equipped with a 3 mm cylindrical die. All extrusion runs were carried out at 65 °C and 30 rpm, conditions that were driven by the processing constraints of the polymer. Drug content evaluation was carried out by dissolving 3 cm lengths of extrudate ($n = 6$) in dichloromethane (DCM), with the amount of drug determined using UV-Vis.

2.7.Surface Morphology of the Extruded PCL Matrices

Scanning electron microscopy (SEM) was used to study the surface morphology of the extruded PCL matrices. Adhesive carbon tabs were used to mount samples on aluminium pin stubs. SEM images of the extrudates were collected using a TM3030 microscope (Hitachi, Tokyo, Japan).

2.8.Mechanical Characteristics of the Extruded PCL Matrices

PCL matrices were fused into ring-shaped devices (outer diameter 5.4 ± 0.1 cm), and underwent compression testing using a TA.XTplus texture analyser (Stable Micro Systems, Surrey, UK). The target compression distance was set at 5 mm, with a test speed of 2 mm/s. The maximum compression force was recorded (in Newtons) for six cycles, with the last five readings averaged to produce the result.

2.9.In Vitro Dissolution Study

Simulated vaginal fluid (SVF) was prepared using 3.51 g NaCl, 2.00 g lactic acid, 1.40 g KOH, 1.00 g acetic acid, 0.22 g $\text{Ca}(\text{OH})_2$, 0.16 g glycerol, 0.40 g urea and 5.0 g glucose, made up to 1 L with distilled water; the pH of this solution was adjusted to pH 4.5 using a 0.1 M hydrochloric acid solution (Owen and Katz, 1999).

Capsules containing 250 mg of MET or MET-MA 1:1 after LAG and HME, were placed in bottles containing 50 mL of SVF and placed in an incubator shaker at 37 ± 0.5 °C and 40 rpm over a 2 h period. The dissolution medium used was 50 mL to imitate the maximum volume of vaginal fluid produced by healthy women, who are neither pregnant nor menopausal (Owen and Katz, 1999) and was carried out under non-sink conditions (MET solubility in SVF pH 4.5 8.97 ± 0.13 mg/mL). Samples (3 mL, n = 3) were taken at predetermined time intervals and replaced with fresh dissolution medium. Where extruded PCL matrices were tested, the extrudate was cut into a specific length (24.6 ± 1.6 cm for 20 % w/w MET) that contained equivalent to 250 mg of MET, bent and fused into a ring-shaped device before being placed in the dissolution bottle. The concentration of MET was determined using UV-Vis at 319 nm using a validated calibration ($y = 32.049x + 0.023$, $R^2 = 0.996$).

2.10. Statistical Analysis

Results from the THEDES LAG vs HME dissolution study were statistically evaluated using a student t-test, where the level of significance was denoted as $P < 0.05$.

3. RESULTS AND DISCUSSION

Formation of a multi-component molecular adduct between MET and a hydrophilic agent represents a strategy to accelerate drug release from PCL matrices, through increase of the drug dissolution rate (Zeitsch, 2000; Zheng et al., 2019). During preliminary screening for suitable coformer candidates, the following criteria were applied: (1) possessing at least one carboxylic acid group, (2) a pKa value that is <5, (3) having a reasonable aqueous solubility, (4) generally recognised as safe (GRAS) status.

Several short-chain fatty acids (SCFAs) and aromatic carboxylic acids that met all pre-set coformer criteria were tested for feasibility of forming a room temperature (RT) THEDES with MET (Table 1) using LAG, an established and cost-effective method of screening multicomponent molecular adducts (Hyun et al., 2019). MA was selected for further study due to its higher aqueous solubility (440.7 g/L 25 °C (Yalkowsky et al., 2010)), low acidic pKa value (1.91 (Kastelic et al., 2010)), and its capability of forming a RT liquid with MET when blended at an equimolar ratio (T_g of the formed liquid measured to be -39.7 ± 3.4 °C, Table 2).

3.1. Mechanochemical Synthesis of MET-MA THEDES via Reactive Extrusion

MET and MA were subjected to thermal analysis and were confirmed to present completion of their respective melting event at 169.5 ± 1.0 °C and 152.5 ± 2.9 °C, respectively (Table 2). The two parent reagents were mixed via LAG at molar ratios from MET:MA 1:9 ($\chi_{\text{MET}} = 0.1$) to 9:1 ($\chi_{\text{MET}} = 0.9$). These binary blends were characterised using DSC and a temperature-composition phase diagram was constructed to better understand the thermal behaviour of the system. To indicate for boundary between the complete liquid phase and the solid-liquid mixed phase (the liquidus line), the end point of the last melting ($T_{\text{m, end}}$) event of each system was used for the plotting of the phase diagram. As shown in Figure 2 and reported in Table 2, at $\chi_{\text{MET}} = 0.9$, a depressed melting of MET was observed (158.8 ± 2.4 °C, as compared to 169.5 ± 1.0 °C for pure MET), as a result of the presence of a small quantity of MA (in accordance with the melting point depression theory). With increasing proportions of MA, further depression of the MET melt was observed with the appearance of a glass transition event at approximately -38.9 ± 1.9 °C. In particular, at $\chi_{\text{MET}} = 0.8$, a T_g at -40.7 ± 0.9 °C was observed in addition to the depressed MET melting at 156.5 ± 1.1 °C. Furthermore, at higher concentrations of MA the T_g remained unchanged whereas the T_m was significantly depressed ($\chi_{\text{MET}} = 0.7$, a T_g was observed at -38.1 ± 1.4 °C and a T_m detected at 123.7 ± 2.9 °C). At $\chi_{\text{MET}} = 0.67$, a T_g was observed at -40.4 ± 4.6 °C and a T_m detected at 106.6 ± 5.0 °C. Interestingly, at

χ_{MET} values of 0.5, 0.4 and, 0.33, only a single T_g was present with no following melting, whereas as the ratio of MET decreases further (at χ_{MET} values of 0.2 and 0.1), the coexistence of a T_g and T_m were observed again. A binary phase diagram (Figure 3) was plotted using the T_g values to indicate transformation from mixed state to complete glass, and the end of the final melting event (inflection temperature of the melting peak) as the liquidus line denoting the endpoint of energy exchange at the boundary between a liquid/solid mixture and complete liquid (Diarce et al., 2015). The absence of the solidus line has been reported in the literature with deep eutectic systems where the eutectic melting point is missing, yet glass transition events are detected across a range of composition ratios (Bica et al., 2011; Wang et al., 2014). In those systems, lidocaine was observed to bond with decanoic acid, oleic acid and, ibuprofen, respectively, via “strong interactions of acid and base” that at certain composition ratios, binary blends did not crystallise at all. The authors have concluded that the deep eutectic behaviour in those systems was a result of charge-assisted hydrogen bonding forming partially ionised states between the binary constituents. A similar phase diagram has been reported by Abbott *et al.* when complexing quaternary ammonium salts such as choline chloride, with coformers that possess proton accepting functionality (Abbott et al., 2004). The binary system presented in the current work also possesses a T_g that is well below the melting point of each starting component, invariant with regard to composition and, results in a RT liquid. Each of these observations supports the conclusion that a THEDES system has formed (Bica et al., 2011). A linear extrapolation using the depressed melting points for MET and MA, respectively, was performed and the theoretical eutectic composition was found to occur at a 1:1 molar ratio of the two parent reagents.

FT-IR spectra (Figure 4) showed that MET exhibited a number of characteristic vibrations, including a broad O-H stretch with the peak at 3209 cm^{-1} accompanied by a sharp band at 3099 cm^{-1} denoting the aromatic $=\text{C-H}$ stretch, the nitrite N-O asymmetric stretches between $1533\text{--}1484\text{ cm}^{-1}$ and, the C-N stretches between $1273\text{--}1264\text{ cm}^{-1}$ (data for N-O and C-N stretches not shown in the presented regions), respectively. The most characteristic vibration for MA, on the other hand, was a strong C=O stretch at 1704 cm^{-1} denoting the H-bonded carbonyl groups, accompanied by a medium band at 1633 cm^{-1} representing the C=C stretch (Maçôas et al., 2001). It is worth noting that in the high wavenumber region ($>2800\text{ cm}^{-1}$) the MA carboxylic -OH bands are very weak, confirming their involvement in strong intramolecular H-bonding between the two carboxylic acid groups. Within the equimolar MET-MA THEDES, a number of unique vibrational band shifts were observed. In particular (as detailed in Table

3), the -OH in MET was seen to have blue-shifted from 3209 cm^{-1} to 3427 cm^{-1} , as a result of breakage of the MA intramolecular bonds freeing up the hydroxyl proton (Chiarinelli et al., 2019). The free water content within the formed THEDES was confirmed using TGA to be less than 2 wt% (data not shown), suggesting the occurrence of free -OH band was not due to the presence of moisture within the sample. Changes were also observed with the MA C=O stretch, where the narrow band present at 1704 cm^{-1} in pure MA was significantly broadened in the THEDES with shift to 1712 cm^{-1} . This broadening and shifting of the C=O stretch may suggest that, unlike the identical and symmetrical interaction patterns shared in pure MA, the two -COOH groups are involved in different interaction mechanisms in the MET-MA THEDES. According to Etter's rule of H-bonding (Etter, 1991), preference for interaction occurs between the -COOH in MA and the imidazole tertiary amine (-N=) from MET, owing to preferential interaction between strongest H-bond acceptor and donor. It is worth noting that an additional small peak was also observed at 1580 cm^{-1} in the equimolar THEDES, indicating the presence of ionised -COO⁻ and formation of a charge-assisted H-bond, as opposed to a completely neutral H-bond (Wang et al., 2014). The subtle blue-shift of the peak of the MA carbonyl band from 1704 cm^{-1} to 1712 cm^{-1} , may suggest substitution of the intramolecular H-bonding within pure MA by the intermolecular -COOH dimer formation within the MET-MA THEDES. The simultaneous broadening and weakening of the MET aromatic =C-H stretch in the THEDES could be a result of a shared proton, with the MA carbonyl forming a C-H...O H-bond, stabilising the neighboring N...H-O bond (Steiner and Desiraju, 1999; Stuart, 2004). The 1:1 eutectic stoichiometry suggested by the binary phase diagram is also in support of the above elucidated interaction pattern.

Owing to the scalability and continuous manner of manufacturing, HME has recently been shown as an efficient means of mechanochemical synthesis for viscous liquid molecular adducts including ILs and DESs. James *et al* recently used HME to produce a well-known choline chloride-urea DES, and showed that this method of manufacture was advantageous as it shows potential to overcome difficulties, such as loss of material in transfer, which could arise from handling highly viscous materials (Crawford et al., 2016). In the current study, a binary physical blend of equimolar MET and MA was also subjected to HME processing. A relatively low extrusion temperature, 65 °C, was chosen to minimise possible influence of extensive thermal input, whilst also enabling processability of the polycaprolactone matrices in latter studies. The synthesised THEDES was collected as liquid drops at the end of the extruder barrel.

352

353 It was interesting that although IR spectra of the extruded MET-MA THEDES showed identical
354 band shifts to that prepared using LAG (Figure 5), the T_g of the extruded equimolar binary
355 liquid, unlike that of the LAG counterpart (-39.7 ± 3.4 °C), was observed at -19.3 ± 2.0 °C (Figure
356 6). It was also noticed that the HME product was considerably thicker in texture and cloudier
357 looking (with visibly observable particulates suspended within the liquid) when compared to
358 the LAG counterpart. It is worth noting that the extent of H-bonding has been reported to
359 inversely correlate with the T_g of the formed systems (Taylor and Zografi, 1998). H-bonding
360 and the THEDES formation may have occurred to a lesser extent throughout the HME process,
361 due to the non-intermeshing nature of the extruder used resulting in a sub-optimal mix between
362 both components. Additionally, the presence of a small amount of residual MeOH from LAG
363 may also contribute to a further depressed T_g in the LAG system. As MET and MA
364 spontaneously form a liquid adduct during extrusion under the chosen processing conditions,
365 the binary system loses interparticular friction upon liquification. It is also worth mentioning
366 that an endothermic event was observed for the equimolar MET/MA THEDES prepared using
367 both LAG and HME between 120-150°C (Figure 6). This was due to the inherent instability of
368 maleic acid under elevated temperature conditions to form maleic anhydride and the
369 subsequent loss of water during the acid-to-anhydride conversion. To enable adequate mixing
370 within a liquid, high speed agitation is usually required. However, a relatively low screw speed
371 of 30 rpm was used in this study, in order to attain a balance between the time the processed
372 materials reside within the extruder and extent of mixing within the system. A short residence
373 time within the extruder barrel results in inadequate mixing and insufficient interactions, while
374 a lengthy residence time can lead to thermal degradation. The addition of PCL into the
375 extrusion as a matrix carrier and processing aid was found to improve mixing intensity, which
376 was lost in the low viscous THEDES only system.

377

378 **3.2.End-to-End Single-step Preparation of THEDES-PCL Matrices**

379 Whilst proven processable using HME for scalable and continuous mechanochemical
380 preparation, THEDESs, as viscous liquid drug product intermediates, can bring challenges to
381 downstream handling. In our previous publications, we have reported that the presence of an
382 excipient melt pool could facilitate favourable mixing between parent cocrystallisation
383 reagents by offering a non-complimentary dispersion medium for improved inter-species
384 molecular interactions (Li et al., 2018, 2016). We also suggested that an appropriate carrier
385 excipient should exhibit rapid solidification upon cooling post extrusion, so that a formulated

matrix wherein cocrystals are suspended, thus negating the handling of intermediate drug product. It was, therefore, attempted in the current work to remove in-process handling through development of an end-to-end single-step HME process for THEDES embedded PCL matrices.

Physical blends of MET, MA (amount equating to a 1:1 molar ratio with respective MET loading) and PCL, at weight fractions of 10 and 20 w/w % MET, were processed via HME using the same extrusion settings described previously (65 °C, 30 rpm). For comparison purposes, binary formulations containing only MET and PCL were also extruded using the same conditions.

PXRD and thermal analysis (Figure 7) suggested that the MET in the MET-PCL binary extrudate had been dispersed within the PCL matrix. This was evident from the significant weakening of the MET melting peak with a noticeable depression of the onset of melting in both the physical mixture and the melt extrudates of the binary MET-PCL blend (Figure 7a), possibly owing to the low melting temperature and low melt viscosity of PCL. The presence of a small residual melting endotherm of MET, however, indicates that such dispersion was incomplete, leaving small amounts of crystalline MET within the PCL melt pool. Interestingly, such trace amount of residual MET crystallinity was not observed in the PXRD patterns (Figure 7b), possibly due to a number of reasons such as the percentage crystallinity and/or the size of remaining crystallites being below the detection limit. When MA was introduced to the system and a ternary MET-MA-PCL blend was extruded, a T_g was observed in the extrudates at -38.2 ± 1.1 °C, indicating that THEDES formation was indeed successful in the presence of PCL (Figure 8). It is notable that the observed THEDES T_g within the THEDES-PCL matrix was similar to that resulted from binary THEDES LAG. Such result suggests that the addition of PCL indeed enabled improved mixing and interactions between MET and MA, possibly through added inter-particulate friction and prolonged residence time (296 ± 23 s). The peak melting temperature of PCL (62.2 ± 0.2 °C) was also shown to be depressed to 54.4 ± 0.3 °C in the THEDES-PCL extrudate (Figure 8). This decrease in the melting point of PCL is an additional indication of favourable mixing and miscibility between the THEDES and PCL (Rim and Runt, 1984).

IR spectra of the PCL extrudates (Figure 9) indicated that the characteristic peaks of the pure MET-MA THEDES, such as those seen at 3427 cm^{-1} , 1712 cm^{-1} , 1619 cm^{-1} and 1580 cm^{-1} and described above (Table 3), were also observed in the THEDES-PCL matrices at 3436 cm^{-1} ,

1719 cm^{-1} , 1618 cm^{-1} and 1586 cm^{-1} , respectively. This data further confirmed that the THEDES formation was not inherently affected by dispersion within an extrudable polymeric carrier. The presence of these peaks and the fact that no melting was observed for either pure MET or MA in the DSC thermogram of the extrudate, could be attributed to successful and complete THEDES conversion.

Mechanical stress testing was carried out on the extruded matrices once they had been fused into ring-shaped vaginal inserts (Figure 10). The compression characteristics of vaginal inserts is extremely important in order to ensure comfort and to prevent damage to the local mucosal tissue (Promadej-Lanier et al., 2009). It has been reported in the literature that poor flexibility of vaginal inserts could result in irritation to, as well as erosion and ulceration of the vaginal mucosa and submucosal tissue (Mishell and Lumkin, 1970). In the current study, the flexural/compressive characteristics of the prepared ring-shaped prototype inserts were examined using a compression test. It was anticipated that a higher force required to compress the fused devices would translate to a stiffer ring. As shown in Figure 11, the average maximum compression force for the 20 % w/w MET loaded MET-PCL and THEDES-PCL inserts were 3.66 ± 0.02 N and 1.08 ± 0.01 N, respectively. It is interesting that both results showed better flexibilities than contraceptive vaginal rings currently on the market (Welsh et al., 2019). This could be due to the fact that the prepared prototypes both had a significantly smaller cross-sectional diameters by comparison to commercial products such as Nuvaring[®], Estring[®], and Femring[®]. The MET alone prototype ring, however, exhibited a 3-folded stiffness and multiple sharp bends along the circumference when compared with the THEDES-loaded counterpart. Such results suggest potential negative impact on the rings' mechanistic characteristics with the incorporation of high melting point drugs within PCL matrices, particularly at elevated drug loadings. The incorporation of those drugs through the use of THEDES technology, therefore, could widen formulation design windows by offering considerably improved flexibility and smoothness when squeezed.

3.3. *In vitro* Dissolution Study

Currently marketed intravaginal dosage forms include emulsions, suspensions, ointments, creams, inserts (tablets and capsules), foams and the more advanced insertable devices (i.e., vaginal rings). The targeted timeframe for the course of drug delivery also ranges from immediate release (IR) to extended release (ER) over several days, weeks or even months. Release from a drug-containing matrix is influenced by various factors, including the

dissolution behaviour of the drug itself and how the drug is dispersed throughout the polymeric matrix. The release of the drug will depend both on the surface area of the drug-containing matrix which is exposed to the dissolution medium, and also the quantity of drug loaded into the matrix (Fernando et al., 2019). For inserts designed with ER profiles, not only is an extended drug release duration required, an initial burst release that gives rise to therapeutically effective drug concentrations at the targeted site is also of paramount importance (Wu and Grainger, 2006). Owing to the inherent hydrophobic nature and extremely slow biodegradation profile, PCL remains much less explored as a drug delivery matrix carrier, when compared with other aliphatic polyesters such as polyglycolide, polylactide, poly-(lactide-co-glycolide) (PLGA), poly(hydroxyl butyrate) and, polydioxanone. One major concern for PCL-based drug delivery platforms is their slow onset of drug dissolution, leading to significant lags in offering therapeutic efficacy. It was intended in the current work, by complexing MET with a highly soluble dicarboxylic acid (MA H₂O solubility 0.79 g/L (Zeitsch, 2000)), to achieve faster and to a higher extent, MET release from the PCL matrices and into the dissolution medium, whilst also maintaining a prolonged drug release profile over a course of 7 days.

The extruded PCL matrices were tested to show an embedded MET content of 94.44 ± 8.49 % and 97.05 ± 5.58 %, for extrudates consisted of only MET-PCL and the MET-MA THEDES-PCL, respectively, demonstrating good uniformity of content. The drug release profile comparing the dissolution of pure MET with that of the neat THEDES (both from LAG and HME) in SVF (Figure 12), showed significantly increased onset and rate of MET dissolution from the RT liquid THEDESs. It can be noted from Table 4 that the THEDESs reached greater than 80 % w/w MET dissolution within 20 min, whilst pure MET powders resulted only 1.3 ± 0.1 % w/w. Such results support the hypothesis that incorporation of MA can successfully enhance the rate of MET dissolution, possibly owing to the fact that the complex formed is already in the liquid state.

It is also worth noting that, in the first 10 min, THEDES manufactured by HME exhibited an even more significant increase in dissolution rate with a DP_{10min} of 69.3 ± 6.9 %, compared to a DP_{10min} of 36.8 ± 10.8 % from the LAG THEDES. It is possible that the insufficient H-bonding between MET and MA after HME was actually responsible for this instant burst of MET dissolution, as the breaking of H-bonds (which requires both energy and time) was possibly a rate-limiting factor in the process of MET release from the THEDES. Such a dissolution rate difference between HME and LAG THEDES became less significant upon time and after 20

min, there was no significant difference between both THEDES dissolution profiles ($P = 0.67$) (Figure 12). This again suggests that higher extent of H-bonding presents a kinetic barrier to MET release, which might be useful in maintaining a prolonged release profile after the initial burst stage.

Release of MET from the PCL matrices is driven by a number of variables, including the loading of MET, porosity of the PCL matrix, solubility of MET in the dissolution medium, and the rate of MET diffusion throughout the PCL pores. The release profiles of THEDES-PCL extrudates, showed both increased initial dissolution rates and extended release of MET release relative to MET-PCL counterparts, throughout a course of 7 days (Figure 13). It was particularly promising that the THEDES-PCL matrix containing 20 % w/w MET was capable of a 'burst release' phase, releasing up to 36.0 ± 0.2 % of the loaded MET by end of the first day (24 hours), whilst the MET-PCL counterpart only reached 14.9 ± 0.6 % MET release (Table 5). By end of day 2 the 20 % w/w THEDES-PCL ring exceeded > 50 % MET release, yet the other rings exhibited significant and undesirable stagnant drug release with hardly much increase in drug percentage compared with the previous day. Such a stagnation could be detrimental to achieving a successful BV treatment, as the lack of boosting doses will result in insufficient bactericidal effects, sustained low concentrations of antibiotic and as a result, leading to increased risks of developing antibiotic resistance in the case where local antibiotic dosing is below the mutation prevention concentration (MPC) threshold (Raymond, 2019). In the case of both the MET-PCL and THEDES-PCL matrices, at lower drug loadings of 10 % w/w MET, the release of MET was a more gradual process as this lesser MET content reduced the concentration gradient required for Fickian diffusion (Dang et al., 2013). In the higher loaded 20 % w/w MET systems, increasing numbers of channels and interconnected pores are to be expected as a result of microcracking effects, which enhances the dissolution rate through facilitating transport of MET through the PCL matrix and into the dissolution medium (Pathak et al., 2014). The remainder of the loaded MET dose within the 20 % w/w THEDES-PCL ring was seen to have been gradually released after day 2 in a zero-ordered fashion ($R^2 = 0.94$) until end of the experiments (day 7).

4. CONCLUSION

This work demonstrated how THEDESs can be used to improve the dissolution rate of an API within a small volume of liquid (non-sink conditions) in order to simulate conditions in the vaginal cavity. Liquid molecular adducts would traditionally be considered as difficult to handle and formulate, due to their highly viscous nature, and subsequently discarded. However, this work proposes an end-to-end preparation of the formulated THEDES into a solid vaginal insert, which circumvents intermediate handling and material transfer steps. The concurrent THEDES synthesis and formulation were carried out using a small scale (≈ 10 g) bench-top melt extruder with basic screw configurations, suggesting promising potential for scaled-up preparations. However, it should be reiterated that the presented formulation strategy does not warrant success unless the reactivity between the THEDES reagents is proven to show preference to interactions between either of the parent reagents and the chosen carrier excipient. The formulated THEDES-PCL matrices resulted in a controlled delivery of MET over 7 days in SVF, proving itself as a viable alternative to oral therapy. Further studies will include investigating the effect of loading a liquid multi-component system into a polymeric excipient on the mechanical properties of the resulting matrix, as well as studies into the stability and shelf-life of these THEDESs.

Figure 1 Structure of (a) metronidazole, (b) maleic acid (c) polycaprolactone and (d) proposed H-bonded structure of the 1:1 MET-MA THEDES.

Figure 2 DSC thermograms of (from top to bottom) MET, MET-MA $\chi_{\text{MET}} = 0.9, 0.8, 0.7, 0.67, 0.5, 0.4, 0.33, 0.2$ and 0.1 physical mixtures and MET, after equilibration at $-65\text{ }^{\circ}\text{C}$ and heating at $10\text{ }^{\circ}\text{C}/\text{min}$ to $200\text{ }^{\circ}\text{C}$. The highlighted region is a zoomed in area to show the T_g of the $\chi_{\text{MET}} = 0.8, 0.7, 0.67, 0.5, 0.4, 0.33$ and 0.2 physical mixtures.

Figure 3 Phase diagram of MET-MA system, with liquidus shown as open circles and the T_g of the binary mixtures shown as filled circles; each plot is the average of three replicates.

546

547
548
549

Figure 4 Overlaid FT-IR spectra in the region of 1800–1500 cm⁻¹ and 3600–2400 cm⁻¹ of (from top to bottom) MET, MA and MET-MA 1:1 THEDES produced using LAG.

550

551
552

Figure 5 Overlaid FT-IR spectra in the region of 1800–1500 cm⁻¹ and 3600–2400 cm⁻¹ of (from top to bottom) MET-MA 1:1 after LAG, and HME.

553
554 555
556
557
558

Figure 6 (a) DSC thermogram of MET-MA 1:1 after LAG (black line), and after extrusion at 65 °C and 30 rpm (red line) and (b) appearance of (i) the physical mixture of an equimolar MET-MA blend and (ii) product after equimolar MET-MA neat extrusion and, (iii) product after equimolar MET-MA LAG.

559

560

561
562
563

Figure 7 (a) DSC thermograms and (b) PXRD patterns of (from top to bottom), (MET-PCL) physical mixture and extrudate containing 20 % w/w MET, PCL and MET. The area highlighted shows the shifted melting point of MET after extrusion.

564

565
566
567

Figure 8 DSC thermograms of MET-MA 1:1 physical mixture and after extrusion, (MET-MA 1:1)-PCL extrudate containing 20 % w/w MET and pure PCL. The area highlighted in the grey box shows the T_g of the MET-MA 1:1 DES.

Figure 9 Overlaid FT-IR spectra in the regions of 1800 – 1500 cm^{-1} and 3600 – 2400 cm^{-1} for (from top to bottom) MET-MA 1:1, (MET-MA 1:1)-PCL physical mixture and extrudate (containing 20 % w/w MET) and pure PCL.

MET-PCL 20wt% MET

MET-MA-PCL 20wt% MET

Figure 10 Photographs depicting MET-PCL and THEDES-PCL loaded matrices, respectively, containing 20 % w/w MET, fused into ring-shaped vaginal inserts.

Figure 11 Average maximum compression force (N) for MET-PCL 20 % w/w MET and (MET-MA 1:1)-PCL 20 % w/w MET where n=3.

Figure 12 Dissolution profiles of MET and MET-MA 1:1 after synthesis through LAG (20 min 22 Hz) and HME (65 °C, 30 rpm) in simulated vaginal fluid. Red and blue circles represent MET-MA 1:1 synthesised through HME and LAG respectively, and black circles represent MET. Each point is representative of the mean $\pm$ S.D. where n = 3.

584

585

586 *Figure 13 Dissolution profiles of melt extruded MET-MA 1:1 formulations in PCL using simulated vaginal fluid. Black and*
 587 *red circles represent MET-PCL and (MET-MA 1:1)-PCL at 10 % w/w MET respectively and blue and green triangles*
 588 *represent MET-PCL and (MET-MA 1:1)-PCL at 20 % w/w MET respectively. Each point is representative of the mean $\pm$*
 589 *S.D. where $n = 3$.*

590 **TABLES**

591 *Table 1 Carboxylic acids that were trialled for formation of a low melting 1:1 molecular adduct with MET, including their name, structure, pKa, aqueous solubility (g/mL) and the melting point*
 592 *or glass transition of the adduct formed after LAG for 5 minutes at 20Hz.*

Acid Name	Structure of Acid	pKa	Aqueous Solubility at 25 °C (g/L) (Yalkowsky et al., 2010)	Peak of acid melt (°C)	T _m /T _g of 1:1 molecular adduct (°C)
Maleic Acid (MA)		1.9, 6.3 (Kastelic et al., 2010)	440.7	134.3±1.1	T _g -39.7±3.4
Azelaic Acid (AZE)		4.5, 5.5 (Martins et al., 2016)	2.4	109.9±0.8	T _m 98.6±0.1
Benzoic Acid (BA)		4.2 (Hollingsworth et al., 2002)	3.4	123.1±1.3	T _m 98.0±0.4
4-Hydroxybenzoic Acid (4-HBA)		3.6 (Hollingsworth et al., 2002)	4.9	216.8±0.1	T _m 118.7±1.6

4-Aminobenzoic
Acid (4-ABA)

2.4, 4.9 (van
de Graaf et al.,
1981)

5.4

187.9±1.0

T_m 122.9±0.1

Salicylic Acid (SA)

3.0
(Stoimenovski
et al., 2010)

2.2

160.2±1.2

T_m 96.9±0.1

594
595

Table 2 Onset and end temperatures of the final melt (liquidus temperature) and mid-point of glass transition temperature measured from the DSC thermograms with differing mole fraction of the MET-MA system.

χ_{MET}	T _g (°C)	T _m (end) (°C)
0.00	-	152.5±2.9
0.10	-41.2±3.5	145.4±3.3
0.20	-35.6±2.2	124.1±1.7
0.33	-36.4±5.9	103.8±8.2
0.40	-39.5±5.2	93.0±4.8
0.50	-39.7±3.4	-
0.60	-41.3±2.4	88.6±6.3
0.67	-40.4±4.6	106.6±5.0
0.70	-38.1±1.4	123.7±2.9
0.80	-40.7±0.9	156.5±1.1
0.90	-	158.8±2.4
1.00	-	169.5±1.0

596

	IR Frequency (cm ⁻¹)	Band Assignment
Metronidazole	3209	O-H stretch (intra H-bonded)
	3099	Aromatic C-H stretch
	1533, 1484	N-O asymmetric stretch
	1273, 1264	C-N stretch
	1073	C-O stretch
	713	=C-H bend
Maleic Acid	2871	O-H stretch
	1704	C=O stretch
	1633	C=C stretch
MET-MA	3427	O-H stretch (free MET)
THEDES	2519	O-H stretch (H-bonded MA)
($\chi_{\text{MET}} = 0.50$)	1712	C=O stretch (broadened)
	1619	C=C stretch
	1580	COO ⁻ stretch

599 *Table 4 Drug percentage (DP %) at defined timepoints for each of the MET drug systems.*

	DP (%)			
	10 mins	20 mins	45 mins	120 mins
MET	0.2±1.3x10 ⁻²	1.3±0.1	5.1±2.5	98.1±10.2
MET-MA 1:1 LAG	36.8±10.8	87.1±7.4	89.3±1.2	103.9±4.8
MET-MA 1:1 HME	69.3±6.9	82.6±7.3	98.0±4.5	101.6±1.3

600

601 *Table 5 Drug percentage (DP %) and dissolution rate (DR %/day) at particular timepoints for the data presented in Figure*
602 *13.*

	DP (%)			DR (%/day)		
	Day 1	Day 2	Day 7	Day 1	Day 2	Day 7
MET (10 % w/w)	11.7±1.5	17.7±1.6	35.6±2.7	11.7±1.5	8.9±0.8	5.1±0.4
MET (20 % w/w)	14.9±0.6	18.4±1.5	43.0±3.6	14.9±0.6	9.2±0.7	6.1±0.5
MET-MA (10 % w/w MET)	16.5±1.9	27.5±2.1	73.6±3.9	16.5±1.9	13.6±1.0	10.4±0.6
MET-MA (20 % w/w MET)	36.0±0.2	55.6±0.8	83.9±4.1	36.0±0.2	27.8±0.4	12.0±0.6

603

REFERENCES

- Abbott, A.P., Ahmed, E.I., Prasad, K., Qader, I.B., Ryder, K.S., 2017. Liquid pharmaceuticals formulation by eutectic formation. *Fluid Phase Equilib.* 448, 2–8.
<https://doi.org/10.1016/j.fluid.2017.05.009>
- Abbott, A.P., Boothby, D., Capper, G., Davies, D.L., Rasheed, R.K., 2004. Deep Eutectic Solvents formed between choline chloride and carboxylic acids: Versatile alternatives to ionic liquids. *J. Am. Chem. Soc.* 126, 9142–9147. <https://doi.org/10.1021/ja048266j>
- Alster, T., 2013. Review of Lidocaine/Tetracaine Cream as a Topical Anesthetic for Dermatologic Laser Procedures. *Pain Ther.* 2, 11–19. <https://doi.org/10.1007/s40122-013-0013-z>
- Aroso, I.M., Craveiro, R., Rocha, Â., Dionísio, M., Barreiros, S., Reis, R.L., Paiva, A., Duarte, A.R.C., 2015. Design of controlled release systems for THEDES - Therapeutic deep eutectic solvents, using supercritical fluid technology. *Int. J. Pharm.* 492, 73–79.
<https://doi.org/10.1016/j.ijpharm.2015.06.038>
- Aroso, I.M., Silva, J.C., Mano, F., Ferreira, A.S.D., Dionísio, M., Sá-Nogueira, I., Barreiros, S., Reis, R.L., Paiva, A., Duarte, A.R.C., 2016. Dissolution enhancement of active pharmaceutical ingredients by therapeutic deep eutectic systems. *Eur. J. Pharm. Biopharm.* <https://doi.org/10.1016/j.ejpb.2015.11.002>
- Bica, K., Shamshina, J., Hough, W.L., MacFarlane, D.R., Rogers, R.D., 2011. Liquid forms of pharmaceutical co-crystals: Exploring the boundaries of salt formation. *Chem. Commun.* 47, 2267–2269. <https://doi.org/10.1039/c0cc04485g>
- Bryan, H.A., Alster, T.S., Koppel, R.A., 2002. The S-Caine peel: A novel topical anesthetic for cutaneous laser surgery. *Dermatologic Surg.* 28, 999–1003.
<https://doi.org/10.1046/j.1524-4725.2002.02079.x>
- Centers for Disease Control and Prevention, 2015. Bacterial Vaginosis - 2015 STD Treatment Guidelines [WWW Document]. CDC.
- Cherukuvada, S., Nangia, A., 2013. Eutectics as improved pharmaceutical materials: design, properties and characterization. *Chem. Commun.* 50, 906–923.
<https://doi.org/10.1039/c3cc47521b>
- Chiarinelli, J., Casavola, A.R., Castrovilli, M.C., Bolognesi, P., Cartoni, A., Wang, F., Richter, R., Catone, D., Tasic, S., Marinkovic, B.P., Avaldi, L., 2019. Radiation damage mechanisms of chemotherapeutically active nitroimidazole derived compounds. *Front. Chem.* 7, 1–

636 14. <https://doi.org/10.3389/fchem.2019.00329>

637 Crawford, D.E., Wright, L.A., James, S.L., Abbott, A.P., 2016. Efficient continuous synthesis of
638 high purity deep eutectic solvents by twin screw extrusion. *Chem. Commun.* 52, 4215–
639 4218. <https://doi.org/10.1039/C5CC09685E>

640 Cunningham, F.E., Kraus, D.M., Brubaker, L., Fischer, J.H., 1994. Pharmacokinetics of
641 intravaginal metronidazole gel. *J. Clin. Pharmacol.* 34, 1060–1065.

642 Dang, N.T.T., Turner, M.S., Coombes, A.G.A., 2013. Development of intra-vaginal matrices
643 from polycaprolactone for sustained release of antimicrobial agents. *J. Biomater. Appl.*
644 28, 74–83. <https://doi.org/10.1177/0885328212437393>

645 Darwish, A., Elshar, E.M., Hamadeh, S.M., Makarem, M.H., 2007. Treatment options for
646 bacterial vaginosis in patients at high risk of preterm labor and premature rupture of
647 membranes. *J. Obstet. Gynaecol. Res.* 33, 781–787. <https://doi.org/10.1111/j.1447-0756.2007.00656.x>

649 Dean, P.M., Turanjanin, J., Yoshizawa-Fujita, M., MacFarlane, D.R., Scott, J.L., 2009.
650 Exploring an anti-crystal engineering approach to the preparation of pharmaceutically
651 active ionic liquids. *Cryst. Growth Des.* 9, 1137–1145.
652 <https://doi.org/10.1021/cg8009496>

653 Diarce, G., Gandarias, I., Campos-Celador, García-Romero, A., Griesser, U.J., 2015. Eutectic
654 mixtures of sugar alcohols for thermal energy storage in the 50-90°C temperature
655 range. *Sol. Energy Mater. Sol. Cells* 134, 215–226.
656 <https://doi.org/10.1016/j.solmat.2014.11.050>

657 Etter, M.C., 1991. Hydrogen bonds as design elements in organic chemistry. *J. Phys. Chem.*
658 <https://doi.org/10.1021/j100165a007>

659 Fernando, H.V., Chan, L.L., Dang, N., Santhanes, D., Banneheke, H., Nalliah, S., Coombes,
660 A.G.A., 2019. Controlled delivery of the antiprotozoal agent (tinidazole) from
661 intravaginal polymer matrices for treatment of the sexually transmitted infection,
662 trichomoniasis. *Pharm. Dev. Technol.* 24, 348–356.
663 <https://doi.org/10.1080/10837450.2018.1481430>

664 Hanson, J.M., McGregor, J.A., Hillier, S.L., Eschenbach, D.A., Kreutner, A.K., Galask, R.P.,
665 Martens, M., 2000. Metronidazole for bacterial vaginosis: A comparison of vaginal gel
666 vs. oral therapy. *J. Reprod. Med. Obstet. Gynecol.* <https://doi.org/10.1097/00006254-200103000-00014>

667

668 Hollingsworth, C.A., Seybold, P.G., Hadad, C.M., 2002. Substituent effects on the electronic
669 structure and pKa of benzoic acid. *Int. J. Quantum Chem.* 90, 1396–1403.
670 <https://doi.org/10.1002/qua.10362>

671 Hyun, S.M., Lee, B.J., Abuzar, S.M., Lee, S., Joo, Y., Hong, S.H., Kang, H., Kwon, K.A., Velaga,
672 S., Hwang, S.J., 2019. Preparation, characterization, and evaluation of celecoxib
673 eutectic mixtures with adipic acid/saccharin for improvement of wettability and
674 dissolution rate. *Int. J. Pharm.* 554, 61–71.
675 <https://doi.org/10.1016/j.ijpharm.2018.10.044>

676 Jones, A., 2019. Bacterial Vaginosis: A Review of Treatment, Recurrence, and Disparities. *J.*
677 *Nurse Pract.* <https://doi.org/10.1016/j.nurpra.2019.03.010>

678 Kastelic, J., Hodnik, Ž., Šket, P., Plavec, J., Lah, N., Leban, I., Pajk, M., Planinšek, O., Kikelj, D.,
679 2010. Fluconazole cocrystals with dicarboxylic acids. *Cryst. Growth Des.* 10, 4943–4953.
680 <https://doi.org/10.1021/cg1010117>

681 Lan, S.F., Kehinde, T., Zhang, X., Khajotia, S., Schmidtke, D.W., Starly, B., 2013. Controlled
682 release of metronidazole from composite poly-ε-caprolactone/alginate (PCL/alginate)
683 rings for dental implants. *Dent. Mater.* 29, 656–665.
684 <https://doi.org/10.1016/j.dental.2013.03.014>

685 Li, S., Yu, T., Tian, Y., Lagan, C., Jones, D.S., Andrews, G.P., 2018. Mechanochemical Synthesis
686 of Pharmaceutical Cocrystal Suspensions via Hot Melt Extrusion: Enhancing Cocrystal
687 Yield. *Mol. Pharm.* 15, 3741–3754.
688 <https://doi.org/10.1021/acs.molpharmaceut.7b00979>

689 Li, S., Yu, T., Tian, Y., McCoy, C.P., Jones, D.S., Andrews, G.P., 2016. Mechanochemical
690 Synthesis of Pharmaceutical Cocrystal Suspensions via Hot Melt Extrusion: Feasibility
691 Studies and Physicochemical Characterization. *Mol. Pharm.* 13, 3054–3068.
692 <https://doi.org/10.1021/acs.molpharmaceut.6b00134>

693 Maçôas, E.M.S., Fausto, R., Lundell, J., Pettersson, M., Khriachtchev, L., Räsänen, M., 2001. A
694 matrix isolation spectroscopic and quantum chemical study of fumaric and maleic acid.
695 *J. Phys. Chem. A* 105, 3922–3933. <https://doi.org/10.1021/jp003802p>

696 Martins, I.C.B., Sardo, M., Santos, S.M., Fernandes, A., Antunes, A., André, V., Mafra, L.,
697 Duarte, M.T., 2016. Packing Interactions and Physicochemical Properties of Novel
698 Multicomponent Crystal Forms of the Anti-Inflammatory Azelaic Acid Studied by X-ray
699 and Solid-State NMR. *Cryst. Growth Des.* 16, 154–166.

700 <https://doi.org/10.1021/acs.cgd.5b01057>

701 Mishell, D.R., Lumkin, M.E., 1970. Contraceptive effect of varying dosages of progestogen in
 702 silastic vaginal rings. *Fertil. Steril.* 21, 99–103. [https://doi.org/10.1016/s0015-](https://doi.org/10.1016/s0015-0282(16)37333-2)
 703 0282(16)37333-2

704 Myer, L., Denny, L., Telerant, R., Souza, M. de, Wright, Jr., T.C., Kuhn, L., 2005. Bacterial
 705 Vaginosis and Susceptibility to HIV Infection in South African Women: A Nested Case-
 706 Control Study. *J. Infect. Dis.* 192, 1372–1380. <https://doi.org/10.1086/462427>

707 Owen, D.H., Katz, D.F., 1999. A vaginal fluid simulant. *Contraception* 59, 91–95.
 708 [https://doi.org/10.1016/S0010-7824\(99\)00010-4](https://doi.org/10.1016/S0010-7824(99)00010-4)

709 Pal, K., Roy, S., Behera, B., Kumar, N., Sagiri, S., Ray, S., 2011. Bacterial vaginosis: Etiology
 710 and modalities of treatment-A brief note. *J. Pharm. Bioallied Sci.* 3, 496.
 711 <https://doi.org/10.4103/0975-7406.90102>

712 Pathak, M., Coombes, A.G.A., Ryu, B.M., Cabot, P.J., Turner, M.S., Palmer, C., Wang, D.,
 713 Steadman, K.J., 2018. Sustained Simultaneous Delivery of Metronidazole and
 714 Doxycycline From Polycaprolactone Matrices Designed for Intravaginal Treatment of
 715 Pelvic Inflammatory Disease. *J. Pharm. Sci.* 107, 863–869.
 716 <https://doi.org/10.1016/j.xphs.2017.09.033>

717 Pathak, M., Coombes, A.G.A., Turner, M.S., Palmer, C., Wang, D., Steadman, K.J., 2015.
 718 Investigation of polycaprolactone matrices for intravaginal delivery of doxycycline. *J.*
 719 *Pharm. Sci.* 104, 4217–4222. <https://doi.org/10.1002/jps.24652>

720 Pathak, M., Turner, M., Palmer, C., Coombes, A.G.A., 2014. Evaluation of polycaprolactone
 721 matrices for the intravaginal delivery of metronidazole in the treatment of bacterial
 722 vaginosis. *J. Biomater. Appl.* 29, 354–363. <https://doi.org/10.1177/0885328214528256>

723 Pedro, S.N., Freire, M.G., Freire, C.S.R., Silvestre, A.J.D., 2019. Deep eutectic solvents
 724 comprising active pharmaceutical ingredients in the development of drug delivery
 725 systems. *Expert Opin. Drug Deliv.* <https://doi.org/10.1080/17425247.2019.1604680>

726 Promadej-Lanier, N., Smith, J.M., Srinivasan, P., McCoy, C.F., Butera, S., Woolfson, A.D.,
 727 Malcolm, R.K., Otten, R.A., 2009. Development and evaluation of a vaginal ring device
 728 for sustained delivery of HIV microbicides to non-human primates. *J. Med. Primatol.* 38,
 729 263–271. <https://doi.org/10.1111/j.1600-0684.2009.00354.x>

730 Ramanujam, R., Sundaram, B., Janarthanan, G., Devendran, E., Venkadasalam, M., John
 731 Milton, M.C., 2018. Biodegradable Polycaprolactone Nanoparticles Based Drug Delivery

732 Systems: A Short Review. Biosci. Biotechnol. Res. Asia.
733 <https://doi.org/10.13005/bbra/2676>

734 Ramukutty, S., Ramachandran, E., 2012. Crystal growth by solvent evaporation and
735 characterization of metronidazole. J. Cryst. Growth 351, 47–50.
736 <https://doi.org/10.1016/j.jcrysgro.2012.04.017>

737 Raymond, B., 2019. Five rules for resistance management in the antibiotic apocalypse, a
738 road map for integrated microbial management. Evol. Appl. 12, 1079–1091.
739 <https://doi.org/10.1111/eva.12808>

740 Rim, P.B., Runt, J.P., 1984. Melting Point Depression in Crystalline/Compatible Polymer
741 Blends. Macromolecules 17, 1520–1526. <https://doi.org/10.1021/ma00138a017>

742 Shamshina, J.L., Barber, P.S., Rogers, R.D., 2013. Ionic liquids in drug delivery. Expert Opin.
743 Drug Deliv. 10, 1367–1381. <https://doi.org/10.1517/17425247.2013.808185>

744 Sheldon, R.A., 2017. The: E factor 25 years on: The rise of green chemistry and sustainability.
745 Green Chem. 19, 18–43. <https://doi.org/10.1039/c6gc02157c>

746 Smith, A., 2018. Metronidazole resistance: A hidden epidemic? Br. Dent. J. 224, 1–2.
747 <https://doi.org/10.1038/sj.bdj.2018.221>

748 Steiner, T., Desiraju, G.R., 1999. The weak hydrogen bond in structural chemistry and
749 biology. Oxford University Press, New York.

750 Stoimenovski, J., MacFarlane, D.R., Bica, K., Rogers, R.D., 2010. Crystalline vs. ionic liquid salt
751 forms of active pharmaceutical ingredients: A position paper. Pharm. Res. 27, 521–526.
752 <https://doi.org/10.1007/s11095-009-0030-0>

753 Stuart, B.H., 2004. Infrared Spectroscopy: Fundamentals and Applications. John Wiley &
754 Sons. <https://doi.org/10.1002/0470011149>

755 Taylor, L.S., Zografi, G., 1998. Sugar–Polymer Hydrogen Bond Interactions in Lyophilized
756 Amorphous Mixtures. J. Pharm. Sci. 87, 1615–1621.

757 Turgut, E.H., Ozyazici, M., 2004. Bioavailability File: Metronidazole. Fabad J. Pharm. Sci. 29,
758 39–49.

759 van de Graaf, B., Hoefnagel, A.J., Wepster, B.M., 1981. Substituent Effects. 7.1 Microscopic
760 Dissociation Constants of 4-Aminoand 4-(Dimethylamino)benzoic Acid. J. Org. Chem.
761 46, 653–657. <https://doi.org/10.1021/jo00317a002>

762 Wagner, K.A., Gibbon, K.J., Strom, T.L., Kurian, J.R., Trepanier, L.A., 2006. Adverse effects of
763 EMLA (lidocaine/prilocaine) cream and efficacy for the placement of jugular catheters

764 in hospitalized cats. *J. Feline Med. Surg.* 8, 141–144.
 765 <https://doi.org/10.1016/j.jfms.2005.10.002>

766 Wan, Y., Xiao, B., Dalai, S., Cao, X., Wu, Q., 2009. Development of polycaprolactone/chitosan
 767 blend porous scaffolds. *J. Mater. Sci. Mater. Med.* 20, 719–724.
 768 <https://doi.org/10.1007/s10856-008-3622-z>

769 Wang, H., Gurau, G., Shamshina, J., Cojocaru, O.A., Janikowski, J., MacFarlane, D.R., Davis,
 770 J.H., Rogers, R.D., 2014. Simultaneous membrane transport of two active
 771 pharmaceutical ingredients by charge assisted hydrogen bond complex formation.
 772 *Chem. Sci.* 5, 3449. <https://doi.org/10.1039/C4SC01036A>

773 Welsh, N.R., Malcolm, R.K., Devlin, B., Boyd, P., 2019. Dapivirine-releasing vaginal rings
 774 produced by plastic freeforming additive manufacturing. *Int. J. Pharm.* 572, 1–8.
 775 <https://doi.org/10.1016/j.ijpharm.2019.118725>

776 Wu, P., Grainger, D.W., 2006. Drug/device combinations for local drug therapies and
 777 infection prophylaxis. *Biomaterials* 27, 2450–2467.
 778 <https://doi.org/10.1016/j.biomaterials.2005.11.031>

779 Yalkowsky, S.H., He, Y., Jain, P., 2010. *Handbook of Aqueous Solubility Data, Second Edi.* ed.
 780 CRC Press, Taylor & Francis Group.

781 Yamashita, H., Hirakura, Y., Yuda, M., Terada, K., 2014. Coformer Screening Using Thermal
 782 Analysis Based on Binary Phase Diagrams. *Pharm. Res.* 31, 1946–1957.
 783 <https://doi.org/10.1007/s11095-014-1296-4>

784 Zeitsch, K.J., 2000. Maleic Acid, in: *The Chemistry and Technology of Furfural and Its Many*
 785 *By-Products.* Elsevier, pp. 225–228. https://doi.org/10.1007/978-3-540-71095-0_6254

786 Zhang, L., Huang, Y., Zhou, Y., Buckley, T., Wang, H.H., 2013. Antibiotic Administration
 787 Routes Significantly Influence the Levels of Antibiotic Resistance in Gut Microbiota.
 788 *Antimicrob. Agents Chemother.* <https://doi.org/10.1128/aac.00670-13>

789 Zheng, K., Li, A., Wu, W., Qian, S., Liu, B., Pang, Q., 2019. Preparation, characterization, in
 790 vitro and in vivo evaluation of metronidazole–gallic acid cocrystal: A combined
 791 experimental and theoretical investigation. *J. Mol. Struct.* 1197, 727–735.
 792 <https://doi.org/10.1016/j.molstruc.2019.07.102>
 793